GlassScriptPhysician profile
Sonia Kapoor
NPI 1306874862
$5,460.31
in general payments reported to CMS, 2019-2025
39 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $262 · 2021: $463 · 2022: $707 · 2023: $1,053 · 2024: $1,110 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,157 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,156.97 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,110.56 | 2021-2025 | |
| Novo Nordisk INC | $869.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $717.12 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $364.32 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $355.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $214.52 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $204.24 | 2022 | |
| Merck Sharp & Dohme LLC | $182.00 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Astellas Pharma US INC | $162.43 | 2019-2024 | Veozah |
| Abbott Laboratories | $144.23 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Biohaven Pharmaceuticals, INC. | $140.29 | 2021 | |
| Glaxosmithkline, LLC. | $106.44 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.59 | 2020-2025 | Jardiance |
| Amgen INC. | $83.24 | 2023-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.81 | 2021-2024 | Xifaxan |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.